Table 1 Characteristics of pediatric patients with gender identity incongruence
General, n = 43 (100%) | Sex assigned at birth | |||
|---|---|---|---|---|
Womenb, n = 25 (58.14%) | Men b, n = 18 (41.86%) | p value | ||
Characteristic | ||||
Age in years at first consultationa | 15 (13–16) | 15 (13–17) | 15 (7–16) | 0.388c |
Age in years at the reported onset of gender nonconformitya | 10 (5–3) | 11 (6–13) | 5 (4–13) | 0.095c |
Years elapsed for the first evaluationa | 3 (1–10) | 3 (1–10) | 3 (2–8) | 0.930 c |
Nationality n (%) | ||||
Colombia | 40 (93.02) | 23 (92) | 17 (94.44) | 0.624d |
Another country | 3 (6.98) | 2 (8) | 1 (5.56) | |
Socioeconomic status n (%) | ||||
Stratum 2 | 5 (11.63) | 2 (8) | 3 (16.67) | 0.173d |
Stratum 3 | 11 (25.58) | 5 (20) | 6 (33.33) | |
Stratum 4 | 11 (25.58) | 8 (32) | 3 (16.67) | |
Stratum 5 | 7 (16.28) | 6 (24) | 1 (5.56) | |
Stratum 6 | 3 (6.98) | 3 (16.67) | ||
No data | 6 (13.95) | 4 (16) | 2 (11.11) | |
Depression. n (%) | ||||
No | 24 (55.81) | 9 (36) | 15 (83.33) | 0.002e |
Yes | 19 (44.19) | 16 (64) | 3 (16.67) | |
Anxiety n (%) | ||||
No | 27 (62.79) | 10 (40) | 17 (94.44) | 0.000 e |
Yes | 16 (37.21) | 15 (60) | 1 (5.56) | |
Self-harm n (%) | ||||
No | 32 (74.42) | 16 (64) | 16 (88.89) | 0.094 b |
Yes | 10 (23.26) | 8 (32) | 2 (11.11) | |
No data/did not report | 1 (2.33) | 1 (4) | ||
Suicide attempt n (%) | ||||
No | 35 (81.40) | 19 (76) | 16 (88.89) | 0.344d |
Yes | 7 (16.28) | 5 (20) | 2 (11.11) | |
No data/did not report | 1 (2.33) | 1 (4) | ||
Use of psychoactive drugs, n (%) | ||||
No | 22 (51.16) | 9 (36) | 13 (72.22) | 0.040d |
Yes | 21 (48.84) | 16 (64) | 5 (27.78) | |
Family history of depression and anxiety, n (%) | ||||
No | 18 (41.86) | 10 (40) | 8 (44.44) | 0.284 e |
Yes | 13 (30.23) | 8 (32) | 5 (27.78) | |
No data/ Did not report | 12 (27.91) | 7 (28) | 5 (27.78) | |
Autism Spectrum Disorder, n (%) | ||||
No | 30 (85.71) | 17 (68) | 13 (72.22) | 0.321 d |
Yes | 5 (69.77) | 4 (16) | 1 (5.56) | |
No data/ Did not report | 8 (18.60) | 4 (16) | 4 (22.22) | |
Use of psychoactive substances, n (%) | ||||
No | 26 (60.47) | 12 (48) | 14 (77.78) | 0.468 d |
Yes | 5 (11.63) | 3 (12) | 2 (11.11) | |
No data/ Did not report | 12 (27.91) | 10 (40) | 2 (11.11) | |
Tanner scale at first consultation, n (%) | ||||
Stage I | 6 (13.95) | 6 (33.33) | ||
Stage II | 2 (4.65) | 1 (4) | 1 (5.56) | 0.000 d |
Stage III | 5 (11.63) | 1 (4) | 4 (22.22) | |
Stage IV | 2 (4.65) | 2 (11.11) | ||
Stage V | 27 (62.79) | 22 (88) | 5 (27.78) | |
No data/ Did not report | 1 (2.33) | 1 (4) | ||
Treatment, n (%) | ||||
Mental health intervention | 20 (46.51) | 13 (52) | 7 (38.39) | 0.003 d |
Puberty Blockers—GnRH analogs | 10 (23.26) | 5 (20) | 5 (27.78) | |
Cross-hormone therapy with testosterone | 7 (16.28) | 7 (28) | ||
Cross-hormone therapy with estrogen | 4 (9.30) | 4 (22.22) | ||
No data/did not report | 2 (4.65) | 2 (11.11) | ||